Sermorelin is prescribed in functional and integrative medicine as part of adult hormone optimization and anti-aging protocols. It does not replace conventional evaluation and treatment of pituitary disorders or confirmed growth hormone deficiency. Clinical contexts in which providers incorporate sermorelin include:

Adult Growth Hormone Decline (Somatopause): The primary off-label use — supporting restoration of GH pulsatility in adults experiencing age-associated GH decline, with associated symptoms including reduced lean body mass, increased visceral adiposity, fatigue, and impaired recovery.

Body Composition: Increased GH and downstream IGF-1 activity supports lean muscle preservation, stimulates lipolysis (fat breakdown), and shifts body composition over time when combined with appropriate nutrition and exercise.

Recovery and Tissue Repair: GH plays a central role in musculoskeletal repair, collagen synthesis, and recovery from physical stress. Sermorelin is incorporated into some recovery protocols for this reason.

Sleep Quality: The majority of daily GH secretion occurs during slow-wave (deep) sleep. Sermorelin administered at bedtime can augment this physiological GH pulse, and many patients report improved sleep quality over the course of treatment.

Bone Density: IGF-1 stimulates osteoblast activity and supports bone mineral density; sermorelin-supported IGF-1 elevation may contribute to long-term skeletal health.

General Anti-Aging and Vitality: Providers in longevity medicine incorporate sermorelin as part of broader protocols addressing the physiological hallmarks of aging.

All adult applications are off-label. Providers should discuss the investigational nature of sermorelin therapy in adults with patients before initiating treatment.

Dosing is individualized by your prescribing provider based on symptom profile, baseline labs (including IGF-1), body weight, and treatment goals. Do not adjust your dose without provider guidance.

Concentration: 0.9 mg/mL Route: Subcutaneous (preferred) or intramuscular injection Typical dosing: 0.2–0.3 mg (200–300 mcg) per injection, once daily Timing: Bedtime administration is strongly preferred — sermorelin stimulates the endogenous nocturnal GH pulse, and administering it at bedtime maximizes physiological alignment. Food intake and elevated blood glucose suppress GH secretion; bedtime dosing typically coincides with a fasted state, improving response. Cycle considerations: Response builds gradually over weeks to months. IGF-1 monitoring at 6–8 weeks is standard practice for dose assessment. Many providers use cyclical protocols (e.g., 5 days on / 2 days off, or monthly breaks) to preserve pituitary sensitivity.

Reconstitution Instructions:

Allow the lyophilized vial to reach room temperature before handling.

Draw the specified volume of bacteriostatic water into the provided syringe.

Inject the diluent slowly down the inner wall of the vial — do not inject directly onto the powder.

Gently swirl to dissolve. Do not shake.

The reconstituted solution should be clear and colorless. Discard if particulate matter or discoloration is present.

Withdraw the prescribed dose volume.

Swab the injection site with an alcohol wipe and allow to dry.

Administer subcutaneously in the abdomen or upper thigh. Rotate injection sites with each dose.

Adult use of sermorelin is off-label. Patients should be counseled on this status before initiating therapy. A baseline evaluation including IGF-1, fasting glucose, and a review of pertinent medical history is standard of care before prescribing.

Contraindications and Caution:

Active malignancy: GH and IGF-1 are mitogenic — they promote cell growth and proliferation. Sermorelin is contraindicated in patients with active malignancy or a history of cancer that may be GH/IGF-1 sensitive (including certain breast, prostate, and colorectal cancers). Oncology consultation is required before any GH secretagogue therapy in patients with a cancer history.

Underactive thyroid (hypothyroidism): GH metabolism is closely linked to thyroid function. Patients with untreated or undertreated hypothyroidism may have a blunted or altered response to sermorelin. Thyroid status should be evaluated and optimized before initiating therapy.

Diabetes and insulin resistance: GH promotes lipolysis and can transiently impair insulin sensitivity and raise fasting glucose. Patients with diabetes, pre-diabetes, or significant insulin resistance require careful monitoring and provider coordination. Sermorelin-stimulated GH increases may necessitate adjustment of antidiabetic medications.

Elevated baseline IGF-1: Sermorelin is not appropriate for patients with already-elevated IGF-1 levels. Baseline IGF-1 measurement is required before initiating therapy.

Intracranial pathology: Active intracranial lesions, pituitary tumors, or recent neurosurgery are contraindications to pituitary-stimulating therapies.

Pregnancy and breastfeeding: Safety data is absent. Use is not recommended.

Pediatric use: This compounded preparation is formulated for adult use. Pediatric GH deficiency is a separate clinical indication requiring specialist management.

Potential Side Effects: Sermorelin is generally well tolerated at therapeutic doses. Reported side effects include:

Injection site reactions: redness, swelling, or transient pain at the injection site (most common)

Flushing or facial warmth shortly after injection

Headache, typically transient

Dizziness or lightheadedness

Nausea, occasionally reported

Fluid retention or mild peripheral edema, particularly early in treatment

Transient increases in fasting glucose or insulin resistance

Somnolence (drowsiness), consistent with the intended bedtime dosing schedule

Serious adverse effects are rare at appropriate doses. Long-term safety data from large randomized trials in adult populations is limited.

Contact your provider promptly if you experience: significant joint pain or swelling, persistent or severe edema, worsening glucose control, unusual headache, visual disturbances, or any new symptom that develops after initiating treatment.

Glucocorticoids (corticosteroids): Chronic or high-dose glucocorticoid use suppresses GH secretion and blunts pituitary response to GHRH stimulation. Patients on corticosteroid therapy may experience reduced sermorelin efficacy. This interaction should be discussed with your prescribing provider.

Insulin and antidiabetic agents: Sermorelin-stimulated GH increases can reduce insulin sensitivity. Patients on insulin, metformin, or other antidiabetic agents require blood glucose monitoring and may need medication adjustments.

Somatostatin analogs (octreotide, lanreotide): Somatostatin is the physiological inhibitor of GH release. Somatostatin analogs will directly antagonize sermorelin's effect at the pituitary and significantly reduce or eliminate its GH-stimulating activity. Concomitant use is contraindicated in the context of sermorelin therapy.

Thyroid hormone: Adequate thyroid hormone levels are required for normal GH axis function. Patients on thyroid replacement therapy should have stable, optimized thyroid levels before and during sermorelin treatment.

Other GH secretagogues (GHRP-2, GHRP-6, Ipamorelin, CJC-1295): Sermorelin is frequently combined with GH-releasing peptides (GHRPs), which stimulate GH release through a complementary receptor pathway (GHS-R / ghrelin receptor). These combinations can produce a synergistic GH pulse. Such combinations require provider oversight and appropriate dose adjustment.

Anabolic steroids: Androgens influence GH/IGF-1 axis activity and may modulate sermorelin response. Patients on testosterone replacement or other anabolic therapy should have their sermorelin protocol designed with this interaction in mind.

Sermorelin therapy warrants routine laboratory monitoring to confirm response and ensure safety:

Before initiating: IGF-1, fasting glucose and HbA1c, thyroid panel (TSH, free T4), comprehensive metabolic panel At 6–8 weeks: IGF-1 (primary efficacy marker), fasting glucose

Ongoing: IGF-1 every 3–6 months; fasting glucose; provider-directed clinical assessment

IGF-1 should be maintained within the age-appropriate normal reference range. Levels significantly above the upper limit of normal may indicate over-stimulation and warrant dose reduction.

Before reconstitution (lyophilized vial):

Refrigerate at 36°F – 46°F (2°C – 8°C)

Protect from light; store in original packaging

Do not freeze

Use before labeled expiration date

After reconstitution:

Refrigerate at 36°F – 46°F (2°C – 8°C)

Use within 28 days of reconstitution

Keep vial capped and protected from light

Discard if the solution becomes cloudy, discolored, or shows visible particulate matter